Amendment Tool

v1.5 25 Mar 2021

For office use QC: No

Short project title*:											
IRAS project ID* (or REC reference if no IRAS project ID is available):											
Sponsor amendment reference number*:											
Sponsor amendment date* (enter as DD/MM/YY):											
Briefly summarise in lay language the main changes proposed in this amendment. Explain the purpose of the changes and their significance for the study. If the amendment significantly alters the research design or methodology, or could otherwise affect the scientific value of the study, supporting scientific information should be given (or enclosed separately). Indicate whether or not additional scientific critique has been obtained (note: this field will adapt to the amount of text entered)*:	This amendment will comprise of the addition of a new site that was not included in the initia IRAS submission; the removal of NHS sites that are not able to recruit into the study; and changes in PIs at a number of sites.										
		(Specific study	,							
Project type (select):		(
		(abase								
Has the study been reviewed by a UKECA-recognised Res Committee (REC) prior to this amendment?:	(Yes		O No							
What type of UKECA-recognised Research Ethics Commit	tee (REC) review	(NHS/HSC REC								
is applicable? (select):		(fence (MoDREC)								
Is all or part of this amendment being resubmitted to the Re Committee (REC) as a modified amendment (i.e. a subst amendment previously given an unfavourable opinion)?		() Yes		No						
Where is the NHS/HSC Research Ethics Committee (REC) that reviewed	England	Wales	Scotland	Northern Irelan						
the study based?:		۲	0	0	0						
Was the study a clinical trial of an investigational medicinal OR does the amendment make it one?:	product (CTIMP)	() Yes		No						
Was the study a clinical investigation or other study of a me does the amendment make it one?:		(Yes		O No						
Does this clinical investigation or other study of a mec require a Notice of No Objection from MHRA Devices			O Yes	No							
Did the study involve the administration of radioactive subs requiring ARSAC review, OR does the amendment introdu	,	() Yes	No							
Did the study involve the use of research exposures to ioni (not involving the administration of radioactive substances) amendment introduce this?:	OR does the	() Yes		No						
Did the study involve adults lacking capacity OR does the a introduce this?:	amendment	() Yes		O No						
Did the study involve access to confidential patient informa direct care team without consent OR does the amendment		() Yes		No						
Did the study involve prisoners OR does the amendment in	ntroduce this?:	() Yes		No						
Did the study involve children OR does the amendment int	roduce this?:	() Yes		No						
Did the study involve NHS/HSC organisations prior to this a	amendment?:	() Yes		O No						
Did the study involve non-NHS/HSC organisations OR doe introduce them?:	es the amendment	() Yes		No						
		England	Wales	Scotland	Northern Irelan						
Lead nation for the study:		۲	0	0	0						
Which nations had participating NHS/HSC organisations participation amendment?	rior to this	Ţ	7	7	7						
Which nations will have participating NHS/HSC organisation	ns after this	~	v	v	_						

Section 2: Summary of change(s)

Please note: Each change being made as part of the amendment must be entered separately. For example, if an amendment to a clinical trial of an investigational medicinal product (CTIMP) involves an update to the Investigator's Brochure (IB), affecting the Reference Safety Information (RSI) and so the information documents to be given to participants, these should be entered into the amendment tool as three separate changes. A list of all possible changes is available on the "Glossary of Amendment Options" tab. To add another change, tick the "Add another change" box.

	Change 1										
Area of change (select)*: Participating Organisations											
indertaking the same activities as existing sites											
The following NHS hospital is to be added into the study: Royal Liverpool University Hospital [PI - Rebecca Oxtoby]											
England	Wales	Scotland Northern Ire									
V V		7	V								
All O So											
ta	aking the same a bital is to be adde England ☑	aking the same activities as existing bital is to be added into the study: R England Wales	aking the same activities as existing sites bital is to be added into the study: Royal Liverpool Un England Wales Scotland V V								

Add another change: 1

	Change 2	2									
Area of change (select)*:	Participating Organisa	ations									
Specific change (select - only available when area of change is selected first)*:	Early closure or withd	drawal of research sites									
Further information (free text - note that this field will adapt to the amount of text entered):	The following NHS dospitals are to be removed from the study: Glangwili General Hospital, The Hywel Dda Health Board [PI - Pagadala Sridhar]; Doncaster Royal Infirmary, Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust [PI - Dinesh Chadha]; Prince Philip Hospital, Hywel Dda Unversity Health Board [PI - Senthil Kumar]; Southend Mid and South Essex Hospital, NHS Southend CCG [PI - Paul Guyler]										
Applicability:	England	Wales	Scotland	Northern Ireland							
Where are the participating NHS/HSC organisations locate by this change?*:	7	7	4	7							
Will all participating NHS/HSC organisations be affected by some? (please note that this answer may affect the categ change):	(O Some									

Add another change: 1

Change 3												
Area of change (select)*:	Researchers											
Specific change (select - only available when area of change is selected first)*:	PI - New PI, or tempo	orary arrangements	s to cover the abse	nce of a PI								
Further information (free text - note that this field will adapt to the amount of text entered):	Lisa Everton will repla University Hospitals T Derby Hospital, Debo Hosptials Dorset NHS Royal United Hospita Tauro as the PI at Be Care Trust.	rust; Jacqueline B rah Broadbent will S Foundaton Trust; Is Bath NHS Found	enfield will replace replace Suzanne ; Emma Paulett wil dation Trust; Carol	Tim England as tl Ragab as the PI a I replace Louise S	he PI at the Royal t University haw as the PI at							
Applicability:	England Wales		Scotland	Northern Ireland								
Where are the participating NHS/HSC organisations locate by this change?*:	7	7	7	7								
Will all participating NHS/HSC organisations be affected by some? (please note that this answer may affect the categor change):	All O Some											
				Add another cha	nge:							

Declaration by the Sponsor or authorised	I delegate
 I confirm that the Sponsor takes responsit I confirm that I have been formally authority 	bility for the completed amendment tool ised by the Sponsor to complete the amendment tool on their behalf
Name [first name and surname]*:	Angela Shone
Email address*:	sponsor@nottingham.ac.uk

Lock for submission

Please note: This button will only become available when all mandatory (*) fields have been completed. When the button is available, clicking it will generate a locked PDF copy of the completed amendment tool which must be included in the amendment submission. Please ensure that the amendment tool is completed correctly before locking it for submission.

Lock for submission

After locking the tool, proceed to submit the amendment online. The "Submission Guidance" tab provides further information about the next steps for the amendment.

Section 4: Review bodies for the amendment

Please note: This section is for information only. Details in this section will complete automatically based on the options selected in Sections 1 and 2.

		Review bodies																	
	UK wide:					Eng	land a	nd Wa	ales:	Scotland:				Northern Ireland:					
	o	Competent Authority MHRA - Medicines	Competent Authority MHRA - Devices	ARSAC	Radiation Assurance	UKSW Governance	REC (MCA)	G	SddWH	A and HCRW Approval	C (AWIA)	рврр	S (RAEC)	National coordinating function	C REC	SC Data Guardians	Prisons	National coordinating function	
	REC	C0 M⊢	Con MHI	AR	Ra		ШК	CAG	ΞH	HRA	REC	B	S		HSC	HS	Pri	_	Categor
Change 1:						(Y)				(Y)				(Y)				(Y)	New sit
Change 2:						(Y)				(Y)				(Y)				(Y)	А
Change 3:						(Y)				(Y)				(Y)				(Y)	А
Overall reviews for the amend	ment:																		
Full review:						Ν				Ν				Ν				Ν	
Notification only:						Y				Υ				Y				Y	
Overall amendment type:	No	on-sub	stantia	l, no s	tudy-v	vide re	view r	equire	d	•									
Overall Category:	А																		